Akums Drugs and Pharmaceuticals Limited (IN:AKUMS)
:AKUMS
AKUMS Stock Chart & Stats
₹420.10
₹13.30(2.17%)
At close: 4:00 PM EST
₹420.10
₹13.30(2.17%)
Day’s Range― - ―
52-Week Range₹410.10 - ₹620.00
Previous CloseN/A
Volume56.90K
Average Volume (3M)11.50K
Market Cap
₹79.84B
Enterprise Value₹75.91B
Total Cash (Recent Filing)₹16.78B
Total Debt (Recent Filing)₹902.87M
Price to Earnings (P/E)26.2
Beta1.32
Next Earnings
Jun 01, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)4.33
Shares Outstanding157,393,980
10 Day Avg. Volume12,021
30 Day Avg. Volume11,497
Financial Highlights & Ratios
PEG Ratio>-0.01
Price to Book (P/B)2.32
Price to Sales (P/S)1.74
P/FCF Ratio36.67
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
₹680.00Price Target Upside61.87% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)24.77
Revenue Forecast (FY)₹48.77B
Bulls Say, Bears Say
Bulls Say
Margin ImprovementSignificant gross-margin expansion to 39.4% and a return to a positive net margin (8.3%) indicate stronger pricing power, better cost control or improved product mix. These durable margin gains enhance earnings quality and cash generation capacity over the medium term.
Deleveraging / Balance Sheet StrengthA dramatic reduction in debt-to-equity to 0.03 materially lowers financial leverage and interest burden. This stronger balance sheet increases financial flexibility for capex, working capital funding and strategic moves, reducing refinancing and solvency risk over coming quarters.
Strong Cash GenerationRobust operating cash flow with positive free cash flow growth and a 1.38 OCF/net income ratio shows high cash conversion. For a CDMO, reliable cash generation supports reinvestment in capacity, working capital for client contracts, and cushions cyclical pharma demand.
Bears Say
Revenue Growth DecelerationTop-line growth sharply decelerated to 1.3% year-on-year after a 13.7% rise the prior year. Sustained slowdown can limit scalable margin improvement and suggests potential exposure to client demand variability, pricing pressure, or slower new contract wins in the medium term.
EBIT Margin ContractionA decline in EBIT margin despite gross-margin gains points to rising operating expenses or inefficiencies. Persisting EBIT pressure reduces retained cash for investment and makes earnings more sensitive to volume swings, posing a risk to medium-term profitability sustainability.
Slight Operating Cash Flow DipAlthough cash flow remains solid, the year-on-year decline in operating cash flow may reflect working capital timing or pressure on collections. If this trend continues it could constrain free cash flow availability for capex or strategic growth in the CDMO business.
Akums Drugs and Pharmaceuticals Limited News
AKUMS FAQ
What was Akums Drugs and Pharmaceuticals Limited’s price range in the past 12 months?
Akums Drugs and Pharmaceuticals Limited lowest stock price was ₹410.10 and its highest was ₹620.00 in the past 12 months.
What is Akums Drugs and Pharmaceuticals Limited’s market cap?
Akums Drugs and Pharmaceuticals Limited’s market cap is ₹79.84B.
When is Akums Drugs and Pharmaceuticals Limited’s upcoming earnings report date?
Akums Drugs and Pharmaceuticals Limited’s upcoming earnings report date is Jun 01, 2026 which is in 52 days.
How were Akums Drugs and Pharmaceuticals Limited’s earnings last quarter?
Akums Drugs and Pharmaceuticals Limited released its earnings results on Feb 05, 2026. The company reported ₹4.332 earnings per share for the quarter, beating the consensus estimate of N/A by ₹4.332.
Is Akums Drugs and Pharmaceuticals Limited overvalued?
According to Wall Street analysts Akums Drugs and Pharmaceuticals Limited’s price is currently Undervalued.
Does Akums Drugs and Pharmaceuticals Limited pay dividends?
Akums Drugs and Pharmaceuticals Limited does not currently pay dividends.
What is Akums Drugs and Pharmaceuticals Limited’s EPS estimate?
Akums Drugs and Pharmaceuticals Limited’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Akums Drugs and Pharmaceuticals Limited have?
Akums Drugs and Pharmaceuticals Limited has 157,393,980 shares outstanding.
What happened to Akums Drugs and Pharmaceuticals Limited’s price movement after its last earnings report?
Akums Drugs and Pharmaceuticals Limited reported an EPS of ₹4.332 in its last earnings report, beating expectations of N/A. Following the earnings report the stock price went down -0.789%.
Which hedge fund is a major shareholder of Akums Drugs and Pharmaceuticals Limited?
Currently, no hedge funds are holding shares in IN:AKUMS
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Akums Drugs and Pharmaceuticals Limited
Akums Drugs and Pharmaceuticals Limited manufactures and sells pharmaceutical products and active pharmaceutical ingredients India and internationally. The company provides drugs, ayurvedic, herbals, toiletries, nutraceuticals, food and dietary supplements, derma and cosmetics, healthcare and hospital products, over-the-counter (OTC) products, active pharmaceutical ingredients, excipients, and compounds. It also offers branded formulations on various dosage forms, including tablets, capsules, injectables, opthalmics, and soft gelatin capsules for therapeutic areas, such as gynaecology, cardiology, orthopaedics, pediatrics, and dermatology, as well as anti-infectives, pain management and gastroenterology. In addition, the company operates as pharmaceutical contract development and manufacturing company. The company was incorporated in 2004 and is based in Delhi, India.
AKUMS Stock 12 Month Forecast
Average Price Target
₹680.00
▲(61.87% Upside)
Technical Analysis
Bafna Pharmaceuticals Limited
―
Bal Pharma Limited
―
Indraprastha Medical Corporation Limited
―
Kopran Limited
―
Wanbury Limited
―